Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application…
Goal is to report initial SC291 clinical data this year Goal is to submit a second IND from the platform this year for SC262, a hypoimmune-modified CD22-targeted allogeneic CAR T therapy…